Selecta Biosciences Inc (NASDAQ:SELB) has been assigned a consensus rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $8.40.
Several research analysts recently commented on the company. Mizuho reissued a “buy” rating and issued a $4.00 price objective on shares of Selecta Biosciences in a research note on Friday, May 10th. Canaccord Genuity reduced their price objective on Selecta Biosciences from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, March 18th. Stifel Nicolaus reissued a “buy” rating and issued a $7.00 price objective on shares of Selecta Biosciences in a research note on Friday, March 15th. Finally, Needham & Company LLC reduced their price objective on Selecta Biosciences to $12.00 and set a “buy” rating for the company in a research note on Monday, January 28th.
NASDAQ SELB traded up $0.11 during mid-day trading on Wednesday, hitting $2.35. The stock had a trading volume of 136,478 shares, compared to its average volume of 228,935. Selecta Biosciences has a twelve month low of $1.41 and a twelve month high of $16.55. The company has a market cap of $105.26 million, a P/E ratio of -0.80 and a beta of 1.50.
Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Selecta Biosciences by 1.5% in the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock valued at $13,956,000 after purchasing an additional 12,916 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Selecta Biosciences during the 3rd quarter valued at $196,000. MetLife Investment Advisors LLC purchased a new stake in Selecta Biosciences during the 3rd quarter valued at $225,000. Vanguard Group Inc boosted its position in Selecta Biosciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock valued at $10,197,000 after buying an additional 6,859 shares during the period. Finally, Fosun International Ltd purchased a new stake in Selecta Biosciences during the 4th quarter valued at $531,000. 47.07% of the stock is owned by institutional investors and hedge funds.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Recommended Story: What is the S&P 500 Index?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.